General Information of Drug (ID: DMFKC7L)

Drug Name
PN-355 Drug Info
Synonyms AndroVir; Tyrosine kinase inhibitors (HIV infection), Paracelsian
Indication
Disease Entry ICD 11 Status REF
Human immunodeficiency virus-1 infection 1C62 Discontinued in Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMFKC7L

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Baricitinib DM4ONW5 Rheumatoid arthritis FA20 Approved [3]
Abrocitinib DM8J29L Atopic dermatitis EA80 Approved [4]
ASP-015K DMZ1UOI Psoriasis vulgaris EA90 Phase 3 [5]
Masitinib DMRSNEU Amyotrophic lateral sclerosis 8B60.0 Phase 3 [6]
KD019 DMEFW3G Brain metastases 2D50 Phase 2 [6]
LEO 124249 DM7W0JE Asthma CA23 Phase 2 [4]
ATI-502 DM8NODR Alopecia ED70 Phase 2 [4]
TD-1473 DMJG7AY Ulcerative colitis DD71 Phase 1 [5]
Aminotriazolopyridine derivative 1 DMW2LZ0 N. A. N. A. Patented [7]
Imidazo[4,5-c]pyridine derivative 2 DMFDRJT N. A. N. A. Patented [7]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tyrosine-protein kinase (PTK) TTJSQEF NOUNIPROTAC Inhibitor [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005490)
2 WO patent application no. 2005,0502,03, Biological materials and uses thereof.
3 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.